News | Stents Carotid | January 05, 2022

Transcarotid Artery Revascularization (TCAR) Versus Carotid Endarterectomy (CEA) Cost-Effectiveness Shows Benefit for Stenting

TCAR was considered cost-effective 49% of the time

With the advent of endovascular technology in the 1990s, carotid angioplasty and stenting (CAS) emerged as an alternative mode of revascularization.

January 5, 2022 – A cost-effectiveness model based on peer-reviewed sources suggests that although five-year costs for transcarotid artery revascularization (TCAR) were higher than those for carotid endarterectomy (CEA), TCAR afforded greater quality-adjusted life years (QALY).

The study is published in the December 2021 issue of the Journal of Vascular Surgery.[1]

Stroke is the fifth leading cause of mortality in the United States, accounting for one in every 19 deaths. Carotid artery disease causes up to 20% of strokes. Since its development in the 1950s, carotid endarterectomy has been the “gold standard” surgical therapy for the treatment of carotid disease. With the advent of endovascular technology in the 1990s, carotid angioplasty and stenting (CAS) emerged as an alternative mode of revascularization.

According to principal author Mahmoud Malas, M.D., from the University of California, San Diego, “TCAR was developed to address the deficiencies associated with both CEA and TFCAS. Several studies have shown that TCAR has one-half the stroke rate of TFCAS. Further, it has similar stroke and death outcomes compared with CEA while reducing the incidence of cranial nerve injury and myocardial infarction.”

“Although the clinical benefits of TCAR have been clearly established, there is little data comparing its cost-effectiveness with CEA,” continues Malas. “The purpose of this study was to compare the quality of life, efficacy, and cost-effectiveness among patients undergoing TCAR versus CEA.”

As reported in JVS, the San Diego group led by Malas created a model that simulated the outcomes of 10,000 symptomatic patients undergoing either TCAR or CEA.  QALY was defined as the product of time and patient quality of life (scale 0-1). Cost-effectiveness was assessed with an incremental cost-effectiveness ratio (ICER) calculated as the incremental costs divided by incremental QALYs. Cost-effectiveness was defined as an ICER <$150,000/QALY.

The team found the 5-year costs per procedure to be $8,821 per 2.85 QALY for CEA and $19,154 per 2.92 QALY for TCAR.

The calculated ICER for TCAR was $152,229 over five years. Based on a nationally accepted standard used by the authors, TCAR was considered cost-effective 49% of the time.

“The present study utilizes microsimulation models to compare the cost, efficacy and cost-effectiveness of TCAR versus CEA in symptomatic patients," said Malas, in discussing the study results. "Although the five-year costs for TCAR were approximately $11,000 greater than those for CEA, it afforded greater QALYs and may be cost-effective in the long term.”

 New technology in patient care may be associated with a significant cost when introduced. It is likely the clinical benefits of TCAR will also prove to be cost-effective as the use of the procedure becomes more common and its costs gradually decrease. 

For more information: www.vascular.org

Find more carotid stenting news

 

Reference:

1. Christina Cui, Ganesh Ramakrishnan, James Murphy, Mahmoud B. Malas. Cost-effectiveness of transcarotid artery revascularization versus carotid endarterectomy. Journal of Vascular Surgery. Published online: June 25, 2021
p1910-1918.e3. DOI:https://doi.org/10.1016/j.jvs.2021.05.051.

 

 


Related Content

Feature | Cardiovascular Business

May 24, 2023 — Park Ridge, N.J.-based publisher Wainscot Media has named Laura Dowden as managing director, group ...

Home May 24, 2023
Home
News | Cardiovascular Business

May 3, 2023 — The Society of Cardiovascular Computed Tomography (SCCT) Board of Directors is proud to announce that ...

Home May 03, 2023
Home
News | Cardiovascular Business

May 2, 2023 — Auburn Community Hospital (ACH) announced today that Dr. Ronald L. Kirshner has been appointed Chair and ...

Home May 02, 2023
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

As we head into Spring, let's take a look at the Top 10 topics that viewers were reading about during the month of April ...

Home May 01, 2023
Home
Feature | Cardiovascular Business | By Emily Gilbert and Kamran Zamanian, PhD

The European interventional cardiology device market is one of the larger markets in the global space. The market is ...

Home April 24, 2023
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

In the blink of an eye yet another month has passed, and here is a look at the Top 10 of what DIcardiology.com viewers ...

Home April 03, 2023
Home
News | Cardiovascular Business

March 29, 2023 — Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging ...

Home March 29, 2023
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

February was a short but busy month in the diagnostic and interventional cardiology world, with a lot of news being ...

Home March 01, 2023
Home
News | Cardiovascular Business

February 17, 2023 — Internationally recognized cardiologist in heart transplantation Jon Kobashigawa, MD, director of ...

Home February 17, 2023
Home
News | Cardiovascular Business

February 9, 2023 — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has entered into a long ...

Home February 09, 2023
Home
Subscribe Now